Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Spermatogenesis associated serine-rich 2-like protein (SPATS2L) is an RNA-binding protein encoded by the SPATS2L gene in humans. It localizes primarily in the cytosol, nucleolus, and nucleoplasm and is involved in the regulation of type I interferon (IFN) signaling as a positive feedback modulator of the JAK/STAT pathway. SPATS2L is upregulated following IFN stimulation and its expression level correlates with disease activity in conditions such as systemic lupus erythematosus, likely contributing to the pathogenesis through amplification of interferon-stimulated gene expression. SPATS2L also plays a role in cell cycle and proliferation processes. While directly targeting SPATS2L is under investigation for diseases like SLE due to its central immunoregulatory role, there are currently no known approved drugs targeting this protein[1][2][4][6].
Modulation of interferon pathway via JAK/STAT signaling (no known approved therapeutic agents directly targeting SPATS2L)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Spermatogenesis associated serine-rich 2-like protein (SPATS2L).